Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme
Authors
Bahl, AMasson, S
Malik, Z
Birtle, A
Sundar, S
Jones, R
James, N
Mason, M
Kumar, S
Bottomley, D
Lydon, A
Chowdhury, S
Wylie, James P
de Bono, J
Affiliation
Bristol Haematology and Oncology Centre, BristolIssue Date
2015-12
Metadata
Show full item recordAbstract
To compile the safety profile and quality of life (QoL) data for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel in the UK Early Access Programme (UK EAP).Citation
Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279). 2015, 116 (6):880-7 BJU IntJournal
BJU InternationalDOI
10.1111/bju.13069PubMed ID
25639506Type
ArticleLanguage
enISSN
1464-410Xae974a485f413a2113503eed53cd6c53
10.1111/bju.13069
Scopus Count
Collections
Related articles
- Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program.
- Authors: Parente P, Ng S, Parnis F, Guminski A, Gurney H
- Issue date: 2017 Dec
- Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
- Authors: Heidenreich A, Bracarda S, Mason M, Ozen H, Sengelov L, Van Oort I, Papandreou C, Fossa S, Hitier S, Climent MA, European investigators
- Issue date: 2014 Apr
- Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.
- Authors: Bracarda S, Gernone A, Gasparro D, Marchetti P, Ronzoni M, Bortolus R, Fratino L, Basso U, Mazzanti R, Messina C, Tucci M, Boccardo F, Cartenì G, Pinto C, Fornarini G, Mattioli R, Procopio G, Chiuri V, Scotto T, Dondi D, Di Lorenzo G
- Issue date: 2014 May
- An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
- Authors: Carles J, Pichler A, Korunkova H, Tomova A, Ghosn M, El Karak F, Makdessi J, Koroleva I, Barnes G, Bury D, Özatilgan A, Hitier S, Katolicka J
- Issue date: 2019 Mar
- Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer.
- Authors: Nozawa M, Mukai H, Takahashi S, Uemura H, Kosaka T, Onozawa Y, Miyazaki J, Suzuki K, Okihara K, Arai Y, Kamba T, Kato M, Nakai Y, Furuse H, Kume H, Ide H, Kitamura H, Yokomizo A, Kimura T, Tomita Y, Ohno K, Kakehi Y
- Issue date: 2015 Oct